Notice of AGM
16 March 2017 11:00 GMT
NOTICE OF ANNUAL GENERAL MEETING
AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2017 and Shareholders' Circular, together with a covering letter from the Chairman.
Copies of the documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The documents are also available on the Company's website at www.astrazeneca.com/agm.
The Company's Annual Report and Form 20-F Information 2016 was published on 7 March 2017.
The above documents are being despatched to shareholders today.
The meeting place for the Annual General Meeting (AGM) will be the Park Plaza London Riverbank Hotel, 18 Albert Embankment, London SE1 7TJ and the AGM will commence at 2.30 pm (BST) on 27 April 2017.
A C N Kemp
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|Esra Erkal-Paler||UK/Global||+44 203 749 5638|
|Vanessa Rhodes||UK/Global||+44 203 749 5736|
|Karen Birmingham||UK/Global||+44 203 749 5634|
|Rob Skelding||UK/Global||+44 203 749 5821|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Craig Marks||Finance, Fixed Income, M&A||+44 7881 615 764|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Mitchell Chan||Oncology||+1 240 477 3771|
|Lindsey Trickett||Cardiovascular & Metabolic Diseases||+1 240 543 7970|
|Nick Stone||Respiratory||+44 203 749 5716|
|Christer Gruvris||Autoimmunity, Neuroscience & Infection||+44 203 749 5711|
|US toll free||+1 866 381 7277|